ImmunityBio Faces Securities Law Lawsuit Over Misleading Statements About Anktiva

ImmunityBio, Inc. (NASDAQ: IBRX) is facing a class action lawsuit alleging violations of securities laws due to misleading statements about its Anktiva medication. The class period spans from January 19, 2026, to March 24, 2026, with a deadline for shareholders to join the case set for May 26, 2026. The lawsuit claims the company misrepresented the drug's capabilities, leading to false public statements.

By DJS Law Group LLP · PR Newswire · April 20, 2026, 07:09 UTC

Tickers: $IBRX

Topics: Anktiva class action ImmunityBio lawsuit securities fraud

Read the full article at PR Newswire

More World news

Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC
Chicago Fed President Austan Goolsbee Expresses Concern Over Persistent Inflation Trends Seeking Alpha · November 12, 2026, 16:33 UTC
Nvidia CEO Jensen Huang Ousted Amid Allegations of Personal Misconduct and National Security Concerns TechCrunch · November 12, 2026, 16:32 UTC
Pomerantz Law Firm Investigates Silvercorp Metals Inc. Following Production Shortfalls and Revenue Decline PR Newswire · November 12, 2026, 16:30 UTC
Cold Spring Harbor Laboratory Raises $6.5 Million at 21st Annual Double Helix Medals Dinner PR Newswire · November 12, 2026, 16:30 UTC
Deloitte Recognized as Leader in IDC MarketScape Worldwide Digital Identity Services Assessment PR Newswire · November 12, 2026, 16:30 UTC
SpaceX Announces $74 Billion Investment in AI Data Center Projects in Texas and Arizona Seeking Alpha · November 12, 2026, 16:25 UTC
Ofcom Fines Meta £450,000 Over Inaccurate WhatsApp Business Data Seeking Alpha · November 12, 2026, 16:25 UTC